Press Releases

September 15, 2021
– Listed on the German national price list and all pharmacy software programs – – Bylvay is approved in U.S. , EU and UK as first drug treatment for patients with PFIC   – – Only once-daily drug indicated to treat all forms of PFIC – BOSTON , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc.
September 8, 2021
BOSTON , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 15,000 shares of Albireo’s common stock and restricted
September 8, 2021
– Bylvay now approved in U.S. , EU and UK as first drug treatment for patients with PFIC   – – Only once-daily drug indicated to treat all forms of PFIC – – MHRA decision based on data from the largest Phase 3 PFIC trial to date – BOSTON , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc.
September 7, 2021
– PRV was granted to Albireo with the FDA approval of Bylvay TM (odevixibat) in July – – Non-dilutive capital further strengthens the Company’s financial position – BOSTON , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing
September 2, 2021
BOSTON , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper , President and Chief Executive Officer, Simon Harford , Chief Financial Officer and other members of the
August 5, 2021
– Bylvay TM (odevixibat) approved in U.S. & EU as o nly once-daily drug indicated for patients with PFIC – – Commercialization underway with Bylvay, first prescriptions received in the U.S. – – German price listing expected in September – – Company to host a conference call and webcast today at
July 29, 2021
— Conference call and webcast to be held at 10:00 a.m. ET —  BOSTON , July 29, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast
July 20, 2021
– Only once-daily drug indicated for the treatment of pruritus in PFIC – – Commercial launch of Bylvay immediate; available for prescription in the coming days – – Rare Pediatric Disease Priority Review Voucher issued to Albireo by the FDA – – Company to host investor conference call on July 21 at